Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi
November 02 2015 - 8:00AM
Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is
developing novel cancer immunotherapies based on tumor-infiltrating
lymphocytes (TIL), today announced that Dr. Laszlo Radvanyi is
leaving his position of chief scientific officer of the company.
"We are grateful for Laszlo's service to the company over the
past year," stated Dr. Elma Hawkins, president and chief executive
officer of Lion Biotechnologies. "During his tenure, we
significantly increased our staff of scientists, established GMP
manufacturing for TIL, filed our first IND, and opened our Phase 2
clinical trial in metastatic melanoma." She added, "We thank Laszlo
for assisting us in our achievement of these milestones and wish
him the best in his next endeavor."
"The data generated to date by the NIH and others demonstrating
durable complete remissions with TIL therapy in melanoma is
exciting," stated Dr. Laszlo Radvanyi. "I am proud to have built a
strong research team at Lion and I am confident they will continue
to develop new and exciting approaches within TIL research." He
concluded, "I wish my colleagues at Lion well in their future
efforts to commercialize this important new immuno-oncology therapy
for patients across multiple solid tumor indications."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology
company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The company's lead product
candidate is an adoptive cell therapy using tumor-infiltrating
lymphocytes (TIL) for the treatment of patients with refractory
metastatic melanoma, and is based on a clinical Cooperative
Research and Development Agreement with the National Cancer
Institute. TIL therapy is also being evaluated in
physician-sponsored clinical trials at MD Anderson Cancer Center
and Moffitt Cancer Center. For more information, please visit
http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties described
in the Company's most recently filed quarterly report on Form 10-Q
and annual report on Form 10-K. Except as permitted by law, the
Company undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACT: Investor Relations
The Trout Group
Gitanjali Ogawa
646-378-2949
Gogawa@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024